Safety of endoscopic ultrasound‐guided fine‐needle aspiration for pancreatic solid mass in the elderly: A single‐center retrospective study.

Aim: There are few reports on the safety of endoscopic ultrasound‐guided fine‐needle aspiration (EUS‐FNA) in the elderly. In this study, we investigated the safety of EUS‐FNA for pancreatic solid masses in patients aged ≥80 years. Methods: This is a single‐center retrospective study. A total of 600 patients with pancreatic solid masses who underwent EUS‐FNA under midazolam‐based sedation at our institution between September 2016 and December 2022 were enrolled in this study. Eligible patients were divided into two groups: an elderly group aged ≥80 (n = 84), as well as a nonelderly group aged ≤79 (n = 516). These two groups were compared. Results: The elderly group required significantly fewer midazolam doses for sedation (P < 0.001). Adverse events occurred in eight patients (1.3%), including one (1.2%) and seven (1.4%) in the elderly and nonelderly groups, respectively (P = 0.90). There were no cases of early adverse events in the elderly group and six cases (1.2%) in the nonelderly group (P = 0.32). There was one case of late adverse events in both the elderly and nonelderly groups (P = 0.14), and both were needle tract seeding. There was no significant difference between the two groups in the proportion of cases in which percutaneous oxygen saturation decreased to ≤90% during the EUS‐FNA. Conclusions: Our analysis suggests that EUS‐FNA for pancreatic solid masses can be safely performed in patients aged >80 years without increasing the adverse event rate compared to nonelderly patients aged <80 years. Geriatr Gerontol Int 2023; 23: 836–841. [ABSTRACT FROM AUTHOR]